Introduction of new paradigm where patients are rewarded by sharing their research data would facilitate large scale screening and gathering of big data on prevention.
AlzheimerChain connects novel Fin-tech industry with screening and preventive initiatives and brain disease research to offer alternative to existing, frequently inefficient ways of Alzheimer's disease research funding. Bridging these areas offers many synergies and brings new opportunities for both fields.
AlzheimerChain main components
AlzheimerChain project consists from three following principal components:
AlzheimerChain application
Will focus on screening test, verbal tests, questionnaires, artificial intelligence mainly in evaluation of MRI, physical activity and cognitive training. Blockchain technology will be used for recording and storing data. Application will be available in both mobile and PC version.
AlzheimerChain - security token
AlzheimerChain has fundraising purpose with the aim to create and develop application, MRI artificial intelligence, patient data storage and physician rewarding mechanism; distributed among investors (launched 01/2020).
AlzheimerCoin - utility coin
AlzheimerCoin is rewarding and motivating patients for their healthy lifestyle, physical activity, cognitive training and sharing their data; distributed among patients and community (launch scheduled in first half of 2021).
Alzheimer's disease important facts
- chronic neurodegenerative disease
- the most common early symptom is difficulty in remembering recent events
- development of effective therapeutics against Alzheimer's disease is one of the major challenges of the 21st century
- current treatment is only symptomatic and provides a relief for up to 3 years; it does not cure the cause of the disease
50 MIL
Alzheimer's disease dementia patients currently worldwide
152 MIL
Alzheimer's disease dementia patients worldwide to reach in 2050
8 % GDP
Worldwide costs associated with care for demented patients expected in 2050
Our team
Jan Pavlik, M.D., MBA
Jan has more than 20 years' experience in pharmaceutical industry in various management positions, including commercial, medical, market access and business development. His last position was Commercial Lead at Biogen Czech Republic. He focused mainly on oncology, neurology (dementia, stroke and multiple sclerosis) and area of rare diseases. Currently he has own consultancy company and provides professional advisory services and complex assistance in the field of health care (including pricing, reimbursement, marketing, SFE). He also serves as senior consultant for several projects focusing on multichannel digital communication in pharmaceutical industry.
prof. Jakub Hort, M.D., Ph.D., FEAN.
Professor of neurology with 25 years of both clinical and scientific experience in brain disorders with focus on Alzheimer's disease. He has published more than 150 scientific articles, organized and specialized clinic for Czech Brain ageing study. He is the first author of European Federation of Neurological Societies guidelines for the diagnosis and management of Alzheimer's disease and other dementias. He founded Czech Alzheimer foundation and served on numerous international and national boards and professional positions related to both Alzheimer's disease research and care.
prof. Martin Valis, M.D., Ph.D.
Prof. of neurology. Head of the Department. Regularly published on the topic in peer reviewed journals with long term experience in drug development, clinical trials and Alzheimer's disease in clinical practice. He has served on numerous boards related to science, clinical care, education and organization of care in neurology.
Julia Zajacova, M.Sc.
Director of FABA LTD., British venture capital company founded by a group of experienced professionals, whose interest is to support teams of people with ambition to influence the world. FABA LTD. supports projects with positive impact on our lives and the environment. Project AlzheimerChain is one of them.
Advisory board
Manfred Windisch, Ph.D.
Expert in pharmacology of diseases of the central nervous system with many years of experience in Neurosciences and preclinical/clinical projects in Europe, North America, Asia & operational management with clear understanding of the challenges and opportunities in a pharmaceutical-Biotech/ CRO relationship. He was involved in clinical research in AD, MCI, PD, ALS and cerebrovascular diseases, organizing and conducting so far about 32 international trials from phase 1 to phase 3. He is a highly active member of the scientific community and has authored about 100 original research articles in peer-reviewed journals.
Sarka Kovandova, M.A.
CEO of Alzheimer Foundation Czech Republic having wide experience in the private and NGO sector. The Alzheimer Foundation is particularly focused on support in the expansion of the diagnostic, medical and therapeutic methods, mediation of co-operation and support among scientists, medical doctors and other health care staff acting in this sphere both in the Czech Republic and abroad, support in research and education of medical doctors and health care staff in patients' care and treatment.
Ondrej Lerch, M.D.
Neurologist, working at the department of neurology, Motol University Hospital in Prague, focusing on management and treatment of patients with dementia. His main research interest is the use of advanced imaging (MRI, DTI) and analytical (machine learning, statistical modeling) methods in early diagnosis of neurodegenerative diseases.
Jiri Cerman, M.D., Ph.D.
Technology scout at the International Clinical Research Center in Brno and neurologist at the Department of Neurology, Charles University. During his 10 years of experience in the clinical research of Alzheimer's disease he has introduced amyloid PET imaging into clinical practice in the Czech Republic. As part of his research into neurodegenerative diseases, he promotes the use of new technologies such as virtual reality in diagnostics, advanced imaging methods, AI and machine learning and big data approach, or the use of blockchain technology in the healthcare system.
Tomas Vetrovsky, M.D., Ph.D
Lecturer and research fellow at the Faculty of Physical Education and Sport, Charles University. His main area of research is physical activity and its impact on health and ageing; he is also interested in behavioral medicine, exercise training in clinical populations, and digital health and mHealth. Before entering academia, he spent 20 years in the business of health and medical communications and participated in the development of numerous interactive projects for both healthcare professionals and patients.
Katerina Sheardova, M.D.
Founder of the Czech national longitudinal project of aging "Czech Brain Aging Study", neurologist and researcher at the International Clinical Research Center of St. Anne's University Hospital in Brno.
In addition to the clinical care of patients with diseases associated with aging, her primary interest is the research of the risk-protective factors of dementia, focusing on preventive life-style measures, mindfulness techniques, and spiritual well-being.
Beata Hauser, M.D., MBA
More then 25 years experience in top management global pharma companies including GSK, Ipsen and Santen. Apart from general management, Beata's focus has been on sales, marketing, and governmental affairs. Voted among Top 25 Business Women in the Czech Republic in 2016, her last position was a Head of Central and Eastern Europe for Santen pharmaceutical company. She has established several healthcare and social affairs foundations, all of which have gained prestige in their respective fields (epilepsy, Alzheimer disease, support of senior people).
David Navratil
Serial entrepreneur in a technologically innovative group focusing on artificial intelligence. The group of A.I. technological start-ups consists of Aireen (recognition system for the diagnosis of diseases of the retina of the human eye), Fiddo (mobile application for dog owners supported by A.I. assistance) and Quantasoft (cutting-edge video analytics and face recognition). Currently in charge of the development of an A.I. technological hub focused on Health & Care and telemedicine, which includes Channel + raising fund that provides media business and investment support. Acting as a consultant for AlzheimerChain project, its product launch on the B2C market and business networking.
Ross Andel, Ph.D.
Professor and Director of the School of Aging Studies and Director of the PhD in Aging Studies program, University of South Florida, FL, USA; Senior Researcher in the International Clinical Research Center at the St. Anne's University Hospital in Brno, Czech Republic; Courtesy Professor in the 2nd Medical Faculty at Charles University in Prague, Czech Republic; and Associate Investigator in the ARC Centre for Excellence in Population Ageing. His main research interests include the examination of risk factors for accelerated cognitive decline and impairment, early identification of cognitive impairment and dementia including Alzheimer's disease, and research specific to our understanding of how work and retirement affect health and aging.
Prof. Michael Hornberger, M.D., Ph.D.
Professor of Applied Dementia Research at the Norwich Medical School, University of East Anglia, UK. Over 15 years expertise in dementia research, with 150 peer-reviewed publications. Research interests focused around development of cognitive and sensor-based measures to detect, manage and treat dementia better. Co-inventor of Sea Hero Quest, the largest citizen science project for Alzheimer's disease with over 4.5 million people contributing data worldwide. Great passion for innovative technologies to involved and help people with dementia and their families.
Jan Bubenik, M.D.
Founder of Bubenik Partners, an executive search firm focusing on the Central and Eastern European region and today serves as its managing partner. Bubenik Partner's client base spans early-stage regional companies to global Fortune 500s. Before starting his own firm, he managed the Prague office of Korn/Ferry International, and prior to entering the executive search industry, Bubenik was a management consultant for McKinsey & Company. In addition to his business activities, he was Chairman of the Corporate Council of Forum 2000 – Vaclav Havel´s foundation. Jan has been also serving on the Executive Committee of Young President Organization (YPO).

AlzheimerChain (ALCH) represents a security token with the entitlement to the profit.





AlzheimerChain (ALCH) is ERC20 token created and hosted on the Ethereum blockchain. ALCH has fundraising purpose to create and develop application, MRI artificial intelligence, patients data storage and physician rewarding mechanism
In order to comply with the AML (Anti Money Laundering) principles of European Union legislation, we require our clients to make an AML and KYC statement in order to avoid any doubt about the origin of the resources collected.


AlzheimerChain (ALCH) sales distribution
There are total 1 520 million ALCH security tokens issued, out of which 350 million are available for sale.
16M
Operations
- PR

221M
AlzheimerChain application, MRI artificial intelligence software development
69M
Sales + marketing
44M
Physicians reward for patients data entry

AlzheimerCoin (ALZ)




AlzheimerChain (ALCH) is ERC20 coin created and hosted on the Ethereum blockchain and represents utility coin. ALZ function is to motivate and reward patients for healthy lifestyle, physical activity, cognitive training and sharing their data.

AlzheimerChain application
AlzheimerChain application will focus on screening test, verbal tests, questionnaires, artificial intelligence mainly in evaluation of MRI, physical activity and cognitive training. Blockchain technology will be used for recording and storing data.
Screening test
Several brief and reliable tests appropriate for identifying potential cognitive problems in people who may be worried about or Alzheimer's disease.
Verbal tests
The verbal fluency tests that evaluate cognitive functions.
Questionaries
Adult dispositional hope scale
Gratitude Questionnaire
Harmony in life scale
Loneliness scale
Perceived stress scale
Subjective vitality scale
Cognitive training
Also called brain training is
a program of regular mental activities purported to maintain or improve one's cognitive abilities.
Evaluation of MRI
Individuals are allowed to upload their MRI scans in order for AI to categorize individual brain into one of the categories.
Physical activity
Users will automatically upload their daily step activities.
MARKETS
Population: 10,5M
Alzheimer's patients: 0.157M
Czech Republic
Cluster1: DACH -Germany, Austria, Switzerland
Population: 100M
Alzheimer's patients: 1.847M

Cluster2: UK+Nordics
Population: 94.7M
Alzheimer's patients: 1.372M



Road map
1
Feb 2020 - Feb 2021
Presale - 40% bonus
1. Sales period - 30% bonus
2. Sales period - 20% bonus
3. Sales period - 10% bonus
4. Sales period - 0% bonus
2
Q2 2020 - Q3 2022
AlzheimerChain application
software development
3
Q2 2021 - Q1 2023
Q2 2021 AlzheimerCoin emission
Q2 2021 Beta version CZ
Q3 2022 Cluster 1 - DACH market entry
Q1 2023 Cluster 2 - UK+Nordics market entry
4
2022 - 2024
Data colletion
AlzheimerChain Foundation s.r.o.
Varšavská 715/36, Prague 2,
Czech Republic
Mailing address
Phone number
E-mail address
+420 737 204 642
neuron@alzheimerchain.com
© 2020 AlzheimerChain Foundation s.r.o. All rights reserved.